GLP-1 Diabetes Drugs Linked to Increased Hair Loss Risk

Millions of people taking GLP-1 drugs like Ozempic and Mounjaro for type 2 diabetes may face an unexpected side effect: hair loss. A large study analyzing medical records from the University of Pennsylvania Health System found that patients using these medications developed alopecia at significantly higher rates than those taking other common diabetes treatments—a finding that adds to growing anecdotal reports of hair shedding among users of these increasingly popular drugs.

Researchers compared alopecia rates across three medication classes by examining electronic health records from patients treated between January 2019 and September 2024. In one analysis, they tracked 12,004 people taking GLP-1 receptor agonists against 15,221 taking SGLT-2 inhibitors, a different class of diabetes drug. In a second comparison, they studied 11,964 GLP-1 users alongside 11,233 people on DPP-4 inhibitors. The GLP-1 class includes semaglutide (sold as Ozempic and Wegovy) and tirzepatide (marketed as Mounjaro and Zepbound).

After adjusting for age, sex, ethnicity, body mass index, and other health factors that might skew the results, the pattern became clear. GLP-1 users developed hair loss at a rate 37 percent higher than those taking SGLT-2 inhibitors—6.91 cases per 1,000 person-years compared to 5.04. The gap widened when comparing GLP-1 users to DPP-4 patients: a 68 percent higher risk, with 6.53 cases per 1,000 person-years versus 3.89. The researchers emphasized that while these relative increases were substantial, the absolute risk remained modest. Most importantly, the hair loss appeared to be non-scarring alopecia, meaning hair follicles stayed intact and regrowth remained possible.

The study did not establish exactly why GLP-1 drugs might trigger hair loss, but the researchers outlined plausible mechanisms. Rapid weight loss—the hallmark effect of these medications—is a well-documented cause of increased hair shedding. The sudden drop in body weight can deplete iron and zinc, both essential nutrients for maintaining normal hair growth cycles. Hormonal shifts accompanying weight loss or the medications themselves could also play a role, though the authors acknowledged that more research would be needed to pin down the cause.

The findings come with important caveats. The study was observational, meaning it could not definitively prove that GLP-1 drugs caused the hair loss—only that the two were associated. Medical records did not contain enough detail to assess how severe the hair loss was, how long it lasted, or whether hair regrew after patients stopped taking the medication. Other unmeasured factors could have influenced the results. Still, the researchers described their work as rigorous, drawing on high-quality data from a large, representative patient population. The results held steady across additional analyses, suggesting the findings were reliable.

For patients and doctors weighing treatment options, the study offers a concrete reason to discuss potential side effects before starting GLP-1 therapy. Hair loss affects quality of life and self-image, and knowing about the risk allows for more informed decision-making. The authors framed their work as extending beyond anecdotal reports to provide systematic evidence that clinicians should be aware of this possible adverse effect. As GLP-1 drugs continue to gain popularity not just for diabetes but for weight loss in people without diabetes, understanding their full range of effects becomes increasingly important.